Commission must reconsider GSK's dual pricing system, says ECJ
This article was originally published in Scrip
The European Commission must look again at whether GlaxoSmithKline's dual pricing system in Spain can be exempted from EC competition rules, the European Court of Justice (ECJ) has said.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.